Clinical Trial Update: Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing eplerenone with spironolactone for ascites due to liver cirrhosis has been withdrawn from further study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ascites
• Cirrhosis

Drugs mentioned

• Inspra (eplerenone)
• Spironolactone (spironolactone)

Snippet

Sponsor: Emma Nilsson | Conditions: Ascites, Cirrhosis | Phase 2 | Status: WITHDRAWN